Skip to main content
Premium Trial:

Request an Annual Quote

Life Technologies Appoints Three Former ABI Board Members; Perkin Elmer Taps von Leoprechting to Head Cell Analysis Unit; Baker Wins Sackler Prize in Biophysics; Singer Joins Exact Sciences' Board; and Others

NEW YORK (GenomeWeb News) – Following last week’s merger of Applied Biosystems and Invitrogen to create Life Technologies, the combined firm has appointed three former directors of ABI to its board: Arnold Levine, George Adam, and William Longfield.
Levine will serve as a member of the board’s Science and Technology Committee, Adam will serve as a member of the Audit Committee, and Longfield will serve as a member of the Compensation and Organizational Committee.
In addition, as previously announced, Life Technologies appointed Mark Stevenson, formerly the president and COO of ABI, to the position of president and COO of the combined firm.
The company disclosed in an SEC filing this week that Stevenson will receive an annual salary of $650,000 with options to purchase up to $3.6 million in shares. He will also receive a cash payment of $6,798,040 related to the termination of his employment agreement with ABI.

PerkinElmer has appointed Achim von Leoprechting to be VP and GM of cellular imaging and analysis solutions. Von Leoprechting formerly was European sales director in PerkinElmer’s Bio-discovery business, and before his tenure with the company he worked at Packard BioScience.

University of WashingtonProfessor of Biochemistry and Howard Hughes Medical Research Institute investigator David Baker has been awarded the 2008 Raymond and Beverly Sackler International Prize in Biophysics. Baker received the honor for his work developing software programs that predict protein structures from amino acid sequences, including the Rosetta program.
The other winners of this year’s award include Martin Gruebele of the University of Illinois, Urbana-Champaign, and Jonathan Weissman of the University of California, San Francisco.

Michael Singer has joined Exact Sciences’ board of directors. Singer is CEO of the BrainScope Company, and he has served as an executive at Revolution LLC, at Microsoft, and at Data Critical.

Frederick Pollock has been named VP of corporate development at High Throughput Genomics. Pollock previously was involved in management, sales, and business development at Affymetrix, and before that he spent 11 years at Amersham Pharmacia Biotech.

Haig Kazazian, a professor of medicine at the University of Pennsylvania School of Medicine has been awarded the Allan Awardfrom the American Society of Human Genetics. Kazazian won the award for his discoveries of the association of chromosome haplotypes with disease-causing mutations and in the field of gene jumping. The award carries with it a $10,000 prize.

Everest Biotech, a developer of research antibodies, has appointed Tim Bernard as head of sales and marketing.
Bernard was formerly managing director of AbD Serotec.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.